MacLeod Alan Robert reported ADRX

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0002154450-26-000004

Machine-readable

Structured copy

Timestamps

Event (reported)

Sep 24, 2026

Published

Sep 28, 2026

Ingested by INSIDER

Nov 5, 02:14 UTC

Last re-read

Nov 5, 02:14 UTC

Extracted facts

Filer

MacLeod Alan Robert

Role

Chief Scientific Officer

Transaction

Grant or awardAs filed: “A”

Asset

ADARx Pharmaceuticals, Inc. — Employee Stock Option (right to buy)

Ticker

ADRX

Shares

170.7K

Price per share

$0

Execution date (reported)

Sep 24, 2026

Owned after transaction

170.7K shares

Days from execution to publication

4

What this establishes

MacLeod Alan Robert filed this Form 4 reporting a grant or award of ADRX on Sep 24, 2026. It became public on Sep 28, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Chief Scientific Officer

MacLeod Alan Robertcik:0002154450

Issuer

ADARx Pharmaceuticals, Inc.cik:0001802369

Revision history · 0

No field has changed since this record was first ingested.